Copper is often used to oxidize low density lipoprotein (LDL) in experiment
s in vitro and is a candidate for oxidizing LDL in atherosclerotic lesions.
The binding of copper ions to LDL is usually thought to be a prerequisite
for LDL oxidation by copper, although estimates of LDL copper binding vary
widely. We have developed and validated an equilibrium dialysis assay in a
MOPS-buffered system to measure copper binding to LDL and have found 38.6 /- 0.7 (mean +/- SEM, n=25) copper binding sites on LDL. The binding was sa
turated at a copper concentration of 10 mu mol/L at LDL concentrations of u
p to 1 mg protein/mL. Copper-binding capacity increased progressively and m
arkedly when LDL was oxidized to increasing extents. Chemical modification
of histidyl and lysyl residues on apolipoprotein B-100 reduced the number o
f binding sites by 56% and 23%, respectively. As an example of the potentia
l of this method to assess the effects of antioxidants on copper binding to
LDL, we have shown that the flavonoids myricetin, quercetin, and catechin
(but not epicatechin, kaempferol, or morin), at concentrations equimolar to
the copper present (10 mu mol/L), significantly decreased copper binding t
o LDL by 82%, 56%, and 20%, respectively.